{"disease":{"id":"relapsed-and-refractory-hematological-malignancies","name":"relapsed and refractory hematological malignancies"},"drugs":{"marketed":[],"pipeline":[],"offLabel":[],"totalMarketed":0,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT04283006","title":"A Study of CD20/CD22 Targeted CAR T-cell Therapy for Relapsed or Refractory Lymphoid Malignancies","phase":"EARLY_PHASE1","overall_status":"RECRUITING","enrollment_count":100,"lead_sponsor_name":"He Huang","has_results":false},{"nct_id":"NCT04626908","title":"Clinical Study of Targeting CD19 and CD22 Chimeric Antigen Receptor T Lymphocytes in the Treatment of Recurrent or Refractory B Cell Non-Hodgkin Lymphoma","phase":"PHASE1, PHASE2","overall_status":"UNKNOWN","enrollment_count":18,"lead_sponsor_name":"He Huang","has_results":false},{"nct_id":"NCT04008524","title":"A Clinical Study of CAR-T Cells in the Treatment of Relapsed and Refractory Hematological Malignancies","phase":"","overall_status":"AVAILABLE","enrollment_count":null,"lead_sponsor_name":"Institute of Hematology & Blood Diseases Hospital, China","has_results":false}],"total":3},"guidelines":[],"source":"Drug Landscape verified database"}